For press inquiries click here to contact us.
Endpoints
Novartis hands Regenxbio $100M in fast cash for vector tech
FierceBiotech
Editas commits $125M to Broad to secure source of genome editing inventions
FierceBiotech
Robert Zeldin to take post at Acceleron as its CMO retires
Xconomy
Alder BioPharmaceuticals Picks Juno’s Robert Azelby for CEO
FiercePharma
Novartis’ brand-new gene therapy player AveXis will build $55M plant, hire 200
FierceBiotech
Grail’s third VC round brings funding total to $1.5B
Xconomy
ORIC Pharmaceuticals Appoints Jacob Chacko CEO
San Francisco Business Times
‘Bursting at the seams,’ this high-profile Peninsula biotech company is moving to a bigger home
FierceBiotech
Loxo RET inhibitor shines in early-phase trial
Please see important disclaimers in the Terms section.
